Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial

•Approximately one in five patients with MS do not have the disease.•The central vein differentiates multiple sclerosis from other white matter lesions.•The central vein sign has not been evaluated in multi-center prospective studies.•CAVS-MS is a prospective multicenter study to validate the centra...

Full description

Saved in:

Bibliographic Details
Published in:	NeuroImage clinical Vol. 32; p. 102834
Main Authors:	Ontaneda, D., Sati, P., Raza, P., Kilbane, M., Gombos, E., Alvarez, E., Azevedo, C., Calabresi, P., Cohen, J.A., Freeman, L., Henry, R.G., Longbrake, E.E., Mitra, N., Illenberger, N., Schindler, M., Moreno-Dominguez, D., Ramos, M., Mowry, E., Oh, J., Rodrigues, P., Chahin, S., Kaisey, M., Waubant, E., Cutter, G., Shinohara, R., Reich, D.S., Solomon, A., Sicotte, N.L.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Inc 01-01-2021 Elsevier
Subjects:	Biomarker Biomarkers Central vein Cross-Sectional Studies Demyelinating disease Diagnosis Humans Magnetic Resonance Imaging MRI Multicenter Studies as Topic Multiple sclerosis Multiple Sclerosis - diagnostic imaging Prospective Studies Regular Susceptibility-weighted imaging T2-weighted imaging Demyelinating disease Susceptibility-weighted imaging Multiple sclerosis Biomarker T2-weighted imaging MRI Diagnosis Central vein
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•Approximately one in five patients with MS do not have the disease.•The central vein differentiates multiple sclerosis from other white matter lesions.•The central vein sign has not been evaluated in multi-center prospective studies.•CAVS-MS is a prospective multicenter study to validate the central vein.•CAVS-MS will useT2-weighted, high-isotropic-resolution, segmented echo-planar MRI. The specificity and implementation of current MRI-based diagnostic criteria for multiple sclerosis (MS) are imperfect. Approximately 1 in 5 of individuals diagnosed with MS are eventually determined not to have the disease, with overreliance on MRI findings a major cause of MS misdiagnosis. The central vein sign (CVS), a proposed MRI biomarker for MS lesions, has been extensively studied in numerous cross sectional studies and may increase diagnostic specificity for MS. CVS has desirable analytical, measurement, and scalability properties. “Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS)” is an NIH-supported, 2-year, prospective, international, multicenter study conducted by the North American Imaging in MS Cooperative (NAIMS) to evaluate CVS as a diagnostic biomarker for immediate translation into clinical care. Study objectives include determining the concordance of CVS and McDonald Criteria to diagnose MS, the sensitivity of CVS to detect MS in those with typical presentations, and the specificity of CVS among those with atypical presentations. The study will recruit a total of 400 participants (200 with typical and 200 with atypical presentations) across 11 sites. T2-weighted, high-isotropic-resolution, segmented echo-planar MRI will be acquired at baseline and 24 months on 3-tesla scanners, and FLAIR* images (combination of FLAIR and T2) will be generated for evaluating CVS. Data will be processed on a cloud-based platform that contains clinical and CVS rating modules. Imaging quality control will be conducted by automated methods and neuroradiologist review. CVS will be determined by Select6 and Select3* lesion methods following published criteria at each site and by central readers, including neurologists and neuroradiologists. Automated CVS detection and algorithms for incorporation of CVS into McDonald Criteria will be tested. Diagnosis will be adjudicated by three neurologists who served on the 2017 International Panel on the Diagnosis of MS. The CAVS-MS study aims to definitively establish CVS as a diagnostic biomarker that can be applied broadly to individuals presenting for evaluation of the diagnosis of MS.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	2213-1582 2213-1582
DOI:	10.1016/j.nicl.2021.102834